Sun Sentinel Palm Beach Edition

To mix versus to match

Science behind shot strategy and expert advice to help decide which COVID booster is best for you

- By Tara Parker-Pope

Deciding which booster shot to get can feel a lot like a choose-your-ownadventu­re book — you’ve got three options, but don’t have a clue which one leads to the best outcome.

The Food and Drug Administra­tion recently authorized a mix-andmatch booster shot strategy that allows eligible adults to pick a booster from one of three COVID19 vaccines — Pfizer-BioNTech, Moderna or Johnson & Johnson — even if it’s different from the one they initially received.

But many people are confused about whether they should switch vaccines for the booster or stick with the one they know. And if they do decide to mix and match, which one should they choose?

Public health officials have declined to recommend a specific shot, leaving it up to individual­s to decide. So what should you do? Here’s a look at the science behind mix-andmatch boosters and some advice from the experts to help you decide.

Why did experts approve mixing and matching?:

One reason is convenienc­e. Since the goal is to get as many people vaccinated as possible and help vulnerable people get boosters quickly, the committees authorized the mix-andmatch strategy. This means if you’ve had Johnson & Johnson or Moderna, but the local pharmacy is only offering Pfizer, you can get whatever shot is available without delay.

But the committee was also following the science. Early studies have shown the mix-and-match strategy not only is safe and effective, but that mixing vaccines also can sometimes create a broader, more potent response than getting multiple doses of a single vaccine.

Why isn’t a specific booster shot recommende­d?: The scientific studies didn’t show a clear winner, but did show that all the shots offered strong antibody response no matter what the combinatio­n.

What did the studies show?: It depends on which set of studies you consider. In June, the National Institutes of Health began its study looking at what happens when people fully vaccinated with Pfizer, Moderna or Johnson & Johnson get a booster of the same vaccine or switch to a new one. The study looked at nine different combinatio­ns of vaccines and boosters, with 50 volunteers in each group.

Early results looked at neutralizi­ng antibodies, which are the specific antibodies that stop the virus and protect you from getting sick. All the booster shots stimulated a neutralizi­ng antibody response, but there were difference­s. Those who received the Moderna vaccine for their first two doses and Moderna as a booster had the highest antibody levels. Second place went to people who got two doses of Pfizer, followed by Moderna.

But it’s important to note that the small study groups weren’t designed to compare which shot was best, and the first studies used a full dose (100 micrograms) of Moderna, and not the half dose that has been approved. It’s possible that difference­s in the study subjects led to the difference in results. And while the difference in antibody levels sounds impressive, it’s probably not all that meaningful in terms of protecting you in the real world.

The biggest difference­s in antibody levels were seen in the Johnson & Johnson recipients, who showed a fourfold rise in neutralizi­ng antibodies after the J & J booster, but had a 76-fold rise after the Moderna booster and a 35-fold increase after a Pfizer booster.

Does that mean if I had Johnson & Johnson, I should definitely switch?: Not necessaril­y. For J & J recipients, there’s another study to consider. This one included 30,000 people and looked at overall protection from the coronaviru­s. That study found that a second dose of J & J, at least two months after the first, resulted in 94% protection against mild to severe cases of COVID-19.

What’s intriguing about the Johnson & Johnson vaccine is that it appears to trigger a different part of the immune system, stimulatin­g not just neutralizi­ng antibodies but also T cells, possibly resulting in more durable protection. The NIH study will eventually look at T-cell response following the various booster shot combinatio­ns, but the data isn’t available yet.

How should I decide which one to pick?: All the booster shots stimulate the immune system, so the answer about which shot to get depends on your priorities and personal risk.

„ Talk to your doctor: Depending on your personal health circumstan­ces — whether you have underlying health problems, or are prone to blood clots or heart problems, or have been undergoing cancer treatment — your physician might have an opinion about which shot is best for you. Different vaccines have different possible side effects.

„ Convenienc­e: If you just want convenienc­e, pick the shot that’s easiest to get.

„ Concerns about risk: People who are particular­ly anxious about COVID-19 may decide to base decisions about booster shots on preliminar­y research and pick Moderna, because of the early research showing it stimulates a higher level of neutralizi­ng antibodies.

„ Familiarit­y: Some people may make decisions based on the experience they had with their first shot. They already know their body handled the first dose with no complicati­ons, so they may be inclined to pick the same vaccine for the booster shot.

Does it matter that the Moderna booster is only half a dose?: The NIH study of booster shots is looking at whether there’s a difference in response between those who received 100-microgram boosters of Moderna and those who received a 50-microgram dose. Those results aren’t available yet, but it seems unlikely there will be much of a difference, if any, say experts.

How long does the booster last? Will I need another one soon?: There’s not an answer to that question yet, but we’ll find out in the coming months as scientists continue to study large groups of people who have been vaccinated and received boosters.

What if I’m not eligible for a booster yet?: Depending on how the guidelines for boosters are interprete­d, roughly 85% of the adult population already may be eligible. But while the evidence is clear that people who are older or immune-compromise­d can benefit from additional shots, the original vaccine doses are still doing a good job protecting people from serious illness and hospitaliz­ation.

 ?? WHITNEY CURTIS/THE NEW YORK TIMES ??
WHITNEY CURTIS/THE NEW YORK TIMES

Newspapers in English

Newspapers from United States